Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.79
+0.4%		$3.76
$2.83
▼
$15.74
$288.78M2.591.62 million shs373,040 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$53.38
-0.9%		$50.88
$7.26
▼
$240.00
$153.09M3.3162,992 shs40,702 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.53%-0.79%-2.58%+1.89%-48.50%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-0.55%-0.90%+1.91%+2.86%+465.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.79
+0.4%		$3.76
$2.83
▼
$15.74
$288.78M2.591.62 million shs373,040 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$53.38
-0.9%		$50.88
$7.26
▼
$240.00
$153.09M3.3162,992 shs40,702 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.53%-0.79%-2.58%+1.89%-48.50%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-0.55%-0.90%+1.91%+2.86%+465.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
1.75
Reduce$8.20117.22% Upside
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.77
Moderate Buy$158.33201.42% Upside

Current Analyst Ratings Breakdown

Latest SPRB and FULC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/17/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$149.00
9/16/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/27/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$123.00 ➝ $104.00
8/13/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOverweight
8/13/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/13/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$150.00 ➝ $144.00
8/12/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/A$6.45 per shareN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M30.70N/AN/A$39.72 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$74.88M-$1.21N/AN/AN/AN/A-25.38%-24.15%10/29/2026 (Estimated)
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$38.97M-$39.78N/AN/AN/AN/A-123.53%-90.35%11/9/2026 (Estimated)

Latest SPRB and FULC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$5.79-$6.68-$0.89-$6.68N/AN/A
7/30/2026Q2 2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.2433-$0.34-$0.0967-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
31.35
31.35
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.05
9.23
9.23

Institutional Ownership

CompanyInstitutional Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%

Insider Ownership

CompanyInsider Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.30%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
5576.30 million70.73 millionOptionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
82.87 million2.75 millionOptionable

Recent News About These Companies

Lake Street initiates coverage of Spruce Biosciences at buy
 |  msn.comhttps://www.msn.com/en-us/news/other/lake-street-initiates-coverage-of-spruce-biosciences-at-buy/ar-AA2cu2ZZ
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-spruce-biosciences-inc-nasdaq-sprb-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-09-18/
Lake Street Capital Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)
September 17 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-lake-street-capital-initiates-coverage-on-spruce-biosciences-nasdaq-sprb-2026-09-17/
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260908229364/en/spruce-biosciences-to-participate-in-the-h.c.-wainwright-28th-annual-global-investment-conference/
Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)
August 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SPRB/pressreleases/4095916/oppenheimer-sticks-to-its-buy-rating-for-spruce-biosciences-sprb/
Q3 EPS Estimates for Spruce Biosciences Cut by HC Wainwright
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q3-eps-estimates-for-spruce-biosciences-cut-by-hc-wainwright-2026-08-28/
Spruce Biosciences stock gains after analyst backs regulatory progress
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-stock-gains-analyst-120916232.html
Spruce Biosciences Announces Launch of MPS3BStudy.com
August 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-announces-launch-mps3bstudy-120000920.html
AWM Investment Company Inc. Makes New $7.94 Million Investment in Spruce Biosciences, Inc. $SPRB
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-awm-investment-company-inc-makes-new-794-million-investment-in-spruce-biosciences-inc-sprb-2026-08-26/
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
August 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-announces-positive-pre-120000241.html
Spruce Biosciences Inc.
August 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SPRB/financials/cash-flow
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 12, 2026  |  aol.comA
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cure-sanfilippo-foundation-national-mps-120000761.html
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-appoints-jessica-cohen-120000826.html
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
July 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-appoints-adrian-quartel-120000027.html
Spruce Biosciences Names Adrian Quartel Chief Medical Officer
July 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/spruce-biosciences-names-adrian-quartel-chief-medical-officer?utm_source=marketbeat.com&utm_medium=referral
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-participate-b-riley-200100145.html
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920525-spruce-biosciences-possibly-first-in-mps-iiib-class-enzyme-replacement-therapy
Spruce Biosciences Joins the Russell 3000® Index
June 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spruce-biosciences-joins-russell-3000-120000230.html
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
June 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/spruce-biosciences-appoints-eric-jordan-120000644.html
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
June 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260608285348/en/spruce-biosciences-announces-long-term-tralesinidase-alfa-enzyme-replacement-therapy-data-in-sanfilippo-syndrome-type-b-mps-iiib-presented-at-the-18th-international-mps-symposium/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$3.78 +0.02 (+0.40%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$53.38 -0.49 (-0.90%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas